Panmira Pharmaceuticals, LLC.

The privately-held European mid-sized pharmaceutical company Chiesi Farmaceutici SPA is hoping an orally active small molecule being developed by acquisition target Atopix Therapeutics Ltd. for

Necessity mothered the build-to-buy strategy. Some thought good times might kill it. At a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate

Financings Biopharma financing in the final quarter of 2012 reached $4.2 billion, a 36% increase over Q3’s $3.1 billion, again boosted by a strong showing from follow-on public offerings. The fourth q

A drug-hunting venture borne out of the Bristol-Myers Squibb Co. / Amira Pharmaceuticals Inc. buyout in 2011 has resulted in a new opportunity for Roche . Under a novel collaboration structur